EarningsQ2 2026 Earnings Report
MX:AGIO Q2 2026 EPS Results
Actual EPS-$30.69
Consensus EPS-$30.06
Beat/MissMissed by -$0.64
One Year Ago EPS-$35.05
MX:AGIO Q2 2026 Revenue Results
Actual Revenue$812.63M
Expected Revenue$479.37M
Beat/MissBeat by +$333.26M
YoY Revenue Growth+259.25%
Earnings Announcement Details
QuarterQ2 2026
Date07/30/2026
TimeBefore Open
Conference CallThursday, July 30, 2026
MX:AGIO Upcoming Earnings
Agios Pharma's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:AGIO Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated substantial commercial momentum (AQVESME launch traction and U.S.-centric revenue), a meaningful near-term regulatory catalyst (Mitapivat PDUFA on Nov 1), and active pipeline expansion (cevidoplenib, AG-236, AG-181), supported by a strong cash position (~$1B). Offsetting these positives are elevated R&D and SG&A spending, a sizable net loss ($100.7M), quarter-to-quarter revenue variability (including a one-time $5M stocking benefit in Q2), and potential pricing/net revenue pressures for a sickle cell indication due to higher Medicaid mix and rebates. On balance, the operational and pipeline progress and the regulatory catalyst outweigh the financial and visibility challenges.Company Guidance
Strong Quarterly Revenue and U.S. Commercial Performance
Total net revenue of $44.7M in Q2 2026, comprised of $40.9M (91.5%) in the U.S. and $3.8M (8.5%) outside the U.S.; revenue benefited from ongoing AQVESME launch momentum.
AQVESME Launch Traction
442 cumulative prescriptions from REMS-certified physicians as of June 30, 2026 (200 additional prescriptions added in Q2); approximately 75% of thalassemia lives covered by payer policies; strong prescription-to-treatment conversion and high fill rates reported.
Near-Term Regulatory Catalyst for Mitapivat
sNDA for Mitapivat in sickle cell disease accepted with priority review and a PDUFA goal date of November 1, 2026; REIGNITE Phase III trial has dosed its first patient, positioning a potential accelerated approval as a meaningful near-term event.
Pipeline Expansion and Advancement
In-licensed cevidoplenib (next-generation oral SYK inhibitor for ITP) and advanced AG-236 into an operationally seamless Phase II/III program in polycythemia vera; AG-181 Phase Ib proof-of-mechanism data in PKU expected in H2 2026.
Encouraging Clinical and Conference Data
10 abstracts accepted at EHA including RISE UP in oral plenary; RISE UP and other data showed hemoglobin responses, clinically meaningful reductions in transfusion burden and improvements in pain/fatigue; open-label thalassemia data showed 60% hemoglobin response in certain cohorts.
Solid Financial Position
Ended the quarter with approximately $1.0B in cash, cash equivalents and marketable securities, cited as providing financial flexibility to support commercial growth and pipeline advancement.
Improved Net Loss Compared to Prior Year
Net loss improved to $100.7M in Q2 2026 versus a net loss of $112.0M in Q2 2025, an improvement of approximately $11.3M (≈10.1% reduction in net loss magnitude).
MX:AGIO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed